Anti-STK17B Antilichaam

Serine/threonine kinase 17B (STK17B), also named as DRAK2, whose gene is located on chromosome 2 (2q32.3), was first reported by Sanjo et al. in 1998 (PMID: 9786912) . STK17B has been identified as a promising therapeutic target for type 1 diabetes, multiple sclerosis, and graft rejection. There are also some reports demonstrated that STK17B was related to apoptosis in various cell types, such as islet β-cells and acute myeloid leukemia cells. Some researches revealed that STK17B was deregulated in some cancers and have important role in cancer progression (PMID: 29445189) . It has an indispensable role in NAFLD/NASH and offer a potential therapeutic arget for this disease (PMID: 34614409) .

Boster Bio Anti-STK17B Antibody catalog # A08711-4. Tested in WB, IHC, ELISA. This antibody reacts with Human.

STK17B

O94768

Human

E.coli-derived human STK17B recombinant protein (Position: V252-D369) .

WB, IHC, ELISA

Immunogen affinity purified.

500 μg/mL

Liquid

12 months from date of receipt, -20°C as supplied. 6 months 2 to 8°C after reconstitution. Avoid repeated freezing and thawing.

https://www.bosterbio.com/datasheet?sku=A08711-4

500 μg/mL antibody with PBS,0.02% NaN3, 1 mg BSA and 50% glycerol.